HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Petition against cosmetic talc

This article was originally published in The Rose Sheet

Executive Summary

Cancer Petition Coalition submitted a citizen petition to FDA May 13 seeking a warning on cosmetic talc powder products regarding link to ovarian cancer, the group announces May 19. Group additionally requests a public hearing to air evidence showing that genital application of talc can result in translocation to the ovary; coalition cites studies documenting increased risks of ovarian cancer by 30% to 60% from dusting genitals with talc power. Request reiterates a 1994 citizen petition denied by FDA seeking warning labels on talc powder. New petition stresses mortality of ovarian cancer for women over 65 has "escalated dramatically since 1975," making ovarian cancer the fourth most common fatal cancer in women. FDA Commissioner Andrew von Eschenbach "has failed to mandate a cancer warning label on talc powder, let alone ban its continued use," despite consistent reports of a correlation between talc powder and ovarian cancer, coalition says. The Environmental Working Group submitted a petition to FDA in 2004 asking the agency to investigate the safety of talc, among other cosmetic ingredients, but the request was denied (1"The Rose Sheet" Oct. 17, 2005, p. 4)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel